To deliver the required biological activity for your program, with both efficacy and safety considerations in mind, our experts will apply their knowledge of:
- Cytotoxic payloads including auristatins, maytansines, anthracyclines, amatoxins, PBD dimers, duocarmycins, and camptothecins
- Different payloads utilized in novel therapeutic modalities such as immunomodulators including TLR or STING agonists, peptides, oligosaccharides, DNA and RNA based oligomers and oligonucleotides, or chelators for radioimmunotherapy.
We apply optimal linker design to mitigate any issues related to the diverse physical chemical properties and stability characteristics of the conjugated payload.
A wide range of analytics are available to provide appropriate characterization to support the evaluation and development of these diverse bioconjugates.